Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
BRISTOL-MYERS SQUIBB (NZ) LIMITED,Nivolumab (with ipilimumab and platinum-based chemotherapy),"Advanced non-small cell lung cancer, 1st line combination therapy, irrespective of PDL-1 status","Nivolumab (with ipilimumab and platinum-based chemotherapy) (OPDIVO, YERVOY)",Community and Hospital,
